Taro Pharma

Sun Pharma has agreed to acquire all of the outstanding ordinary shares of Taro for $43 per share in cash without interest, as per the definitive merger agreement.

Sun Pharma arm Taro Pharma reports Q2 net profit at $8.5 million; revenue rises 13.4%

Taro Pharma's net profit and operating income was adversely impacted by a one-time exceptional expense in Q2.

Sun Pharma sets sights on remaining stake in Taro for $38 per share

Taro, whose shares are up 25% in after-hours trading on May 26, has formed a special committee to evaluate the offer.

Sun Pharma surges 3% as subsidiary Taro posts strong Dec qtr show

Taro Pharma reported net sales of USD 176.4 million and is higher by 13 percent. The net profit rose 422 percent to USD 93.5 million. The operating performance by company also witnessed a boost.

Sun Pharma up 4%, drops wind energy plan; Barclays upgrades

Barclays has upgraded Sun Pharma to overweight from equalweight, given the favorable risk-reward following the 40 percent share price decline from its peak in April 2015.

Taro Pharma Q2 profit falls 7% on lower revenue, EBITDA

Operating income was down 22 percent to USD 125 million in quarter ended September 2015 compared to USD 160.27 million in corresponding quarter of last fiscal.

Sun Pharma Q1 profit tanks 46% on Ranbaxy integration cost

Revenue met expectations, growing 10 percent to Rs 6,767.6 crore in June quarter compared to Rs 6,157 crore in March quarter.

Ranbaxy integration may hurt Sun Pharma's Q1 earnings

According to average of estimates of analysts polled by CNBC-TV18, net profit is seen rising 0.6 percent sequentially to Rs 894 crore and revenue may increase 1.7 percent to Rs 6,262 crore in the quarter ended June.

Taro Pharma Q1 profit jumps 125%, sales volumes decline 10%

Revenue grew by 65 percent to USD 215 million compared to USD 130.2 million year-on-year. The NYSE-listed company said revenue in Q1FY15 was negatively impacted by a USD 79 million provision for price protection. June quarter‘s price protection provision was USD 14 million, it added.

Sun Pharma shares rise; HSBC says buy, Ranbaxy & Halol key

According to HSBC, Ranbaxy cost synergies and Halol resolution are the key near-term catalysts for Sun Pharma.

Lupin, Cadila Health, Alembic Pharma up 1-3% on USFDA nods

Lupin and Alembic Pharma both got US FDA nods for antidepressant drug Desvenlafaxine Succinate while Sun Pharma's subsidiary Taro Pharma received approval for anti-allergic tablet Desloratadine.

Sun Pharma gains, brokerages bet on Taro's performance

Investors continued to buy shares of Sun Pharmaceutical Industries on Tuesday after CLSA has retained its high conviction buy rating on the stock with a target of Rs 1,130.

Here's why pharma sector will continue outperforming

Analysts at Motilal Oswal believe that Lupin, Ranbaxy, Cadila Healthcare, GSK Pharma, Torrent Pharma and Alembic Pharma will report stronger overall operational performance during this quarter.

Stocks in news: Apollo Tyres, SKS, Future Lifestyle, Trent

Apollo Tyres | Jain Irrigation | BHEL | SKS Microfinance | Mercator | Bharti Airtel | Canara Bank | Sun Pharma | Hindalco Industries | Reliance Power | Tata Steel | Future Lifestyle Fashion and Trent are stocks, which are in the news today.

Sun Pharma Q3 net up better-than-expected 32% at Rs 881cr

Sun Pharmaceutical Industries beat street expectations on Friday with a third quarter net profit of Rs 881 crore, up 32 percent year-on-year, helped by strong growth across its businesses, including arm Taro Pharma.

Sun Pharma wins over Taro with higher offer

Sun Pharmaceutical Industries has upped the buy-out price for its Israeli unit Taro Pharma by 60%, winning over Taro's board and ending a long battle to gain full control of the US listed drugmaker.

US FDA plant approvals: Positive for Ipca Labs, Cadila

After a long wait, Ipca Laboratories has finally received approval for its Indore facility from the US FDA. This facility along with its Silvassa facility would be now used to manufacture drugs to the US market.

Special committee of Taro Pharma rejects Sun buyout offer

A special committee set up by Taro Pharma board to review Sun Pharma‘s buyout offer has rejected the offer as inadequate, eight months after the offer was made, reports Archana Shukla of CNBC-TV18.

Raging Cap opposes Sun Pharma's offer, calls it inadequate

Sun Pharma’s plans to acquire 100% in its Israeli subsidiary Taro Pharma has hit another roadblock. A second shareholder raging capital management opposed Sun's offer of USD 24.5 per share, terming it grossly inadequate, reports CNBC-TV18, Archana Shukla.

Sun's merger plans: Taro's shareholders may play spoilsport

The Sun Pharma stock rallied 3% today after the drug-maker offered to acquire 100% in the Israeli drug-firm Taro Pharma in which it has 66% stake. While the move got a thumbs-up from analysts, some of Taro’s large shareholders may play spoilsport, reports CNBC-TV18's Archana Shukla.